neuroreha 2019; 11(01): 20-24
DOI: 10.1055/a-0829-5693
Schwerpunkt
© Georg Thieme Verlag KG Stuttgart · New York

Neurologische Rehabilitation – Wohin geht die Reise?

Übersetzung von Jan Mehrholz
Birgitta Langhammer
,
Katharina S. Sunnerhagen
,
Johan K. Stanghelle
Further Information

Publication History

Publication Date:
15 March 2019 (online)

Zusammenfassung

In diesem Beitrag liegt der Schwerpunkt auf der Zukunft bzw. den zukünftigen Herausforderungen der Neurorehabilitation im Zusammenhang mit genetischer Forschung, Behandlungen, Interventionen und Medikamenten zur Verbesserung der Ergebnisse sowie auf translationalen Fragen der Leistungserbringung zwischen spezialisierten und gemeindebasierten Diensten.

 
  • Literatur

  • 1 Barnes MP. Principles of neurological rehabilitation. Journal of Neurology, Neurosurgery, and Psychiatry 2003; 74 (Suppl. 04) iv3-iv7
  • 2 Battié MC, Levalahti E, Videman T. et al. Heritability of lumbar flexibility and the role of disc degeneration and body weight. Journal of Applied Physiology 2008; 104: 379-385
  • 3 Bovend’Eerdt TJH, Botell RE, Wade DT. Writing SMART rehabilitation goals and achieving goal attainment scaling: A practical guide. Clinical Rehabilitation 2009; 23: 352-361 doi:10.1177/0269215508101741
  • 4 Chollet F, Tardy J, Albucher JF. et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): A randomised placebo-controlled trial. The Lancet Neurology 2011; 10: 123-130 doi:10.1016/S1474–4422(10)70314–8
  • 5 Curtis CL, Goldberg A, Kleim JA. et al. Translating genomic advances to physical therapist practice: A closer look at the nature and nurture of common diseases. Physical Therapy 2016; 96: 570-580 doi:10.2522/ptj.20150112
  • 6 Donaghy M. Principles of neurological rehabilitation. In: Donaghy M. ed. Brain‘s diseases of the nervous system. 12. ed.. Oxford: Oxford University Press; 2009
  • 7 Graham C, Lewis S, Forbes J. et al. The Focus, Affinity and Effects trials studying the effect(s) of fluoxetine in patients with a recent stroke: Statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials 2017; 18: 627-627 doi:10.1186/s13063–017–2385–6
  • 8 Ioannidis JP, Karassa FB. The need to consider the wider agenda in systematic reviews and meta-analyses: Breadth, timing, and depth of the evidence. BMJ 2010; 341: c4875
  • 9 Katzmarzyk PT, Gledhill N, Pérusse L. et al. Familial aggregation of 7-year changes in musculoskeletal fitness. The Journals of Gerontology Series A, Biological Sciences And Medical Sciences 2001; 56: B497-B502
  • 10 Ortega-Alonso A, Pedersen NL, Kujala UM. et al. A twin study on the heritability of walking ability among older women. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2006; 61: 1082-1085
  • 11 Pajala S, Era P, Koskenvuo M. et al. Contribution of genetic and environmental effects to postural balance in older female twins. Journal of Applied Physiology 2004; 96: 308-315
  • 12 Turner-Stokes L. et al. Cost-efficient service provision in neurorehabilitation: Defining needs, costs and outcomes for people with long term neurological conditions. A report prepared on behalf of the UK Rehabilitation Outcomes Collaborative (UKROC) steering group. Im Internet: www.kcl.ac.uk/nursing/departments/cicelysaunders/research/studies/uk-roc/Short-Extract-Scentific-summary-29.07.15.pdf Stand: 08.01.2019
  • 13 Wade DT, Halligan PW. Do biomedical models of illness make for good healthcare systems?. BMJ (Clinical Research Ed) 2004; 329: 1398-1401
  • 14 Wade DT. Describing rehabilitation interventions. Clinical Rehabilitation 2005; 19: 811-818